Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Isabella McCary"'
Autor:
Lance Ballester, Christine Guelcher, Isabella McCary, Jan G. Kuhn, Gita Massey, Michael F. Guerrera, Leslie Raffini, Regina Butler
Publikováno v:
Haemophilia. 26:631-636
INTRODUCTION Emicizumab is a recombinant humanized bispecific antibody that bridges factor IXa and factor X to mimic the cofactor function of factor VIII. It is approved to prevent bleeding in patients with haemophilia A (HA). Outside of clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0919b1cd2f9d18a9378b5626e9daae3b
https://doi.org/10.1111/hae.14005
https://doi.org/10.1111/hae.14005
Autor:
Isabella McCary, Christine Guelcher, Jan G. Kuhn, Lance Ballester, Michael F. Guerrera, Regina Butler, Leslie Raffini, Gita Massey
Publikováno v:
Blood. 134:1137-1137
Introduction Emicizumab is a recombinant humanized monoclonal antibody that bridges factor IXa and Factor Xa and is administered via subcutaneous injection. After initial FDA approval for patients with hemophilia A (HA) and inhibitors, it was approve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d370b348d50179741bd4cd48c4381536
https://doi.org/10.1182/blood-2019-122569
https://doi.org/10.1182/blood-2019-122569
Autor:
Jan G. Kuhn, Gita Massey, Michael F. Guerrera, Regina Butler, Leslie Raffini, Christine Guelcher, Isabella McCary
Publikováno v:
Blood. 134:2396-2396
Introduction Emicizumab is a recombinant humanized monoclonal antibody that bridges factor IXa and Factor X and is administered via subcutaneous injection. It provides protection against bleeding in patients with hemophilia A (HA) with and without in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0326fe4ca1d0e6ac51a586ebea89ce96
https://doi.org/10.1182/blood-2019-126944
https://doi.org/10.1182/blood-2019-126944